Pivotal Announces Scientific Presentation at the 17th World Congress on Heart Disease Demonstrating Superiority of VASCAZEN? Unique Formulation

Woodbridge, Ontario (ots/PRNewswire) -

Pivotal Therapeutics Inc. (OTCQX:PVTTF) (CNSX:PVO), a specialty
pharmaceutical company with a focus on cardiovascular health, is
pleased to announce that data from a scientific study related to the
company's product VASCAZEN(TM) concluded that highly purified
Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) with a 6:1
ratio caused potent endothelium-dependent relaxations of isolated
blood vessels, relaxations superior to that of other pure EPA:DHA
ratios (1:1) and only 100% EPA or only 100% DHA.

The study authored by F. Zgheel, M. Alhosin, C. Auger and V.B.
Schini-Kerth, entitled The highly purified EPA:DHA 6:1 product evokes
potent endothelium-dependent relaxations of porcine coronary artery
rings via the redox-sensitive PI3-kinase/Akt-dependent
phosphorylation of eNOS was presented at the 17th World Congress on
Heart Disease - Annual Scientific Sessions 2012 on July 29thin
Toronto, Canada and will be presented at the European Society of
Cardiology (ESC) in Munich, Germany on August 27, 2012.

The scientific study conducted at the University of Strasbourg,
Illkirch, France demonstrated that a specific (EPA) and (DHA) ratio
and purity are important factors in the ability of Omega-3 products
to cause endothelium-dependent relaxations of coronary arteries. "We
are very excited that the VASCAZEN(TM) formulation was superior to
the other existing commercial products in the marketplace in terms of
sustained coronary vasodilation (i.e. increase of blood flow) which
is important for patients with Coronary Heart Disease who have
compromised coronary vessels" stated Dr. George Jackowski Chairman
and Chief Scientific Officer of Pivotal Therapeutics Inc.

About Pivotal Therapeutics Inc.

With offices in Toronto, Canada and Boca Raton, Florida, Pivotal
Therapeutics is a publicly traded (OTCQX: PVTTF) (CNSX: PVO)
specialty pharmaceutical company with a focus on the treatment of
cardiovascular disease. Pivotal Therapeutics' lead product
VASCAZEN[TM] is a prescription medical food formulated to meet the
dietary Omega-3 deficient needs of patients with cardiovascular
disease through elevating (EPA) and (DHA) to levels associated with
reduced risk of cardiovascular complications.

VASCAZEN[TM] is a >90% pure, proprietary EPA:DHA fatty acid
formulation, protected by a series of both issued and pending US and
foreign patents and commercialized by prescription only.

OMAZEN[TM] is a >90% pure, proprietary EPA:DHA fatty acid
formulation commercialized for sale and distribution in Canada for
the maintenance of good health through elevating Omega-3 fatty acid
levels. The unique formulation and dosage will be available to
patients and consumers who realize the health benefits of Omega-3
supplementation with a quality product.

Disclosure Notice

The information contained in this document is as of August 9,
2012. This press release contains forward-looking statements. Such
forward-looking statements are subject to a number of risks,
assumptions and uncertainties that could cause Pivotal's actual
results to differ materially from those projected in such
forward-looking statements. These statements can be identified by the
use of words such as "will", "anticipate", "estimate", "expect",
"project", "forecast", "intend", "plan", "believe", "project",
"potential", and similar expressions with any discussion of future
operating or financial performance or events. In particular, factors
that could cause actual results to differ materially from those in
forward looking statements include the following: Pivotal's inability
to obtain additional financing on acceptable terms; growth in costs
and expenses; inability to compete with others who provide comparable
products; risk that the Company's products will not gain widespread
market acceptance; risks relating to the Company's ability to
maintain its CSNX listing. Forward-looking statements speak only as
of the date made and are not guarantees of future performance. The
Company undertakes no obligation to publicly update or revise any
forward-looking statements contained in this document as a result of
new information or future events or developments. CNSX has not
reviewed and does not accept responsibility for the adequacy or
accuracy of this information.

For further information:
Company Contacts:
Kristine DiMatteo
Investor Relations and Public Affairs
Phone: +1-905-856-9797 ext. 231
E-Mail: kdimatteo@pivotaltherapeutics.us
Rachelle MacSweeney
President
Phone: +1-905-856-9797
E-Mail: rmacsweeney@pivotaltherapeutics.us
Pivotal Therapeutics Inc.
http://www.pivotaltherapeutics.us

ots Originaltext: Pivotal Therapeutics Inc
Im Internet recherchierbar: http://www.presseportal.de